101 results about "Fucosylation" patented technology

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as "RE mutations") per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody¬ dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The invention discloses a production method of fucosylated oligosaccharide. The core of the method is as follows: the GDP-D-rhamnose is converted into the GDP-L-fucose by using the GDP-D-rhamnose-3, 5-epimerase; the GDP-D-rhamnose is obtained by converting the GDP-D-mannose-4, 6-dehydratase and the GDP-4-keto-6-deoxy D-mannose reductase by taking the GDP-D-mannose as a substrate, and the GDP-D-rhamnose is obtained by taking the GDP-D-mannose as a substrate. The invention relates to a method for producing a fucosylated oligosaccharide, which is characterized in that a GDP-D-mannose-4, 6-dehydratase, a GDP-4-keto-6-deoxyD-mannose reductase, a GDP-D-rhamnose-3, 5-epimerase and a fucosyltransferase are expressed in a genetically modified host cell, and the fucosylated oligosaccharide can be produced by the way mentioned above.

The invention relates to a method for producing 6 '-fucosylated chitosan disaccharide GlcNacbeta1-4 (Fucalpha1-6) GlcNAc through double-bacterium coupling fermentation, and belongs to the technical field of fermentation engineering. The method comprises the following steps: taking fucose and N-acetyl-D-glucosamine as substrates in a fermentation system; the 6 '-fucosylated chitosan disaccharide is produced through coupled fermentation of an engineering escherichia coli strain and yeast, and a GlcNAcbeta1-4 (Fucalpha1-6) GlcNAc synthesis pathway including N-acetylhexosamine 1-kinase nahK, fucosyltransferase nodZ, L-fucose kinase Fkp and N, N-diacetylchitosan phosphorylase Chbp is constructed in the engineering escherichia coli, so that the 6'-fucosylated chitosan disaccharide is obtained. According to the invention, the yeast is added to realize cyclic regeneration from GMP to GTP, so that not only is the problem of high oligosaccharide production cost caused by pure exogenous supplement of GTP effectively solved, but also efficient production of GlcNAcbeta1-4 (Fucalpha1-6) GlcNAc is realized, and the yield of GlcNAcbeta1-4 (Fucalpha1-6) GlcNAc is increased to 25.50 g / L by an optimized coupling fermentation production technology. The invention provides a novel synthesis technology of complex N-glycans, and has a wide application prospect.

Herein are antibodies or antigen-binding fragments specifically binding to GPRC5D. Additionally, monovalent antibodies or antigen-binding fragments specifically binding to GPRC5D are also included. The Fc region of these antibodies contains K248E and T437R mutations (designated as “RE mutations”) per the EU numbering system. The described antibodies, expressed in host cells that lack fucosylation capabilities, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.

This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.

The present invention relates to inhibitors of protein fucosylation. More specifically, the present invention relates to carbocyclic compounds of formula (I) useful as inhibitors of protein fucosylation, or for the treatment of cancer, autoimmune diseases, infectious diseases, inflammatory diseases, or sickle cell diseases.

The invention belongs to the field of food, particularly relates to a nutritional composition and application thereof in improving immune disorder, and more particularly relates to application of the nutritional composition in preparing food for improving filial generation body inflammatory factor level disorder caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; in addition, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-8), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to regulate filial generation immunity.

The invention provides agonistic and non-agonistic antibodies that specifically bind Glucocorticoid-induced TNFR-related (GITR) protein, comprising a modified human constant region (Fc) and optionally reduced fucosylation content. Also provided are polynucleotide sequences encoding the antibodies, pharmaceutical compositions thereof and methods of treating cancer.

The present disclosure provides methods for generating antibody compositions that comprise a desired or predetermined or preselected level of total afucosylated (TAF) glycoform. In an exemplary embodiment, the method comprises maintaining glycosylation-capable cells in a cell culture medium comprising fucose and / or glucose at a specific concentration as described herein, the specific concentration being dependent on the level of the desired TAF glycoform. Related compositions comprising glycosylated proteins and their TAF glycoforms are also provided. Cell culture media are also provided.

The present invention relates to use of an enzyme that cleaves both alpha- and beta-1,4-glycosidic bonds and, more particularly, the present invention provides α-L-fucosidase which has α-1,4-glucosidase and β-1,4-galactosidase activities and thus is capable of producing glucose and / or galactose, which are monosaccharides, from non-fucosylated saccharides. The enzyme has transglycosylation activity and thus produces maltooligosaccharides having a higher degree of polymerization than maltooligosaccharides used as a substrate, thereby being applicable to the development of high-value-added new materials in the food industry.

The invention discloses a method, a system and equipment for evaluating the treatment effect of 2-Flurofuse on acute kidney injury. It is found for the first time that 2FF can treat acute kidney injury through the regulation effect on core fucosylation, an EMT process, an ERK signal channel and inflammation; the invention provides a method, a system and equipment for evaluating the treatment effect of 2FF on acute kidney injury on the basis of fucosylation and a method, a system and equipment for evaluating the treatment effect of 2FF on acute kidney injury on the basis of EMT for the field. The method, the system and the equipment are used for assisting clinicians in evaluating the treatment effect of patients with acute kidney injury.

This provides an inhibitor of protein fucosylation. [Solution] A method for inhibiting the fucosylation of a protein, or a fragment or derivative thereof, comprising contacting a eukaryotic cell or mammal with a specific carbocyclic compound or a salt thereof.

Compositions, systems, and kits are disclosed that comprise at least one immune checkpoint inhibitor and at least one immune cell type for adoptive cell therapy, wherein the at least one immune cell type has been fucosylated ex vivo (fuco-ACT). Also disclosed are methods of making and using the compositions, systems, and kits.

The invention belongs to the technical field of quality control products of tumor markers such as carbohydrate antigens, and particularly relates to a liquid quality control product of tumor markers containing multiple carbohydrate antigens, which takes human serum as a matrix and comprises the following components: A, non-analytes including blocking proteins, B, non-analytes including C and D; the blocker is a functional protein obtained by modifying a blocker through fucosylation, and a fucose-containing sugar chain structure is introduced through enzymolysis and glycosylation, so that the blocker can specifically recognize a fucose-containing Si-Lea epitope shared by carbohydrate antigens; the B analyte comprises carbohydrate antigens and other markers, and the other markers comprise tumor markers and non-tumor related markers. Aiming at the problems of obvious cross reaction of carbohydrate antigens and insufficient stability of liquid quality control products, the invention provides a multi-component synergistic system taking blocker protein as a core, and high uniformity, stability and detection convenience of the liquid quality control products are realized by specifically combining carbohydrate antigen conserved epitopes and dynamically blocking the cross reaction.

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or social emotional development in a subject wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the subject is an infant, a young child, or a child.

The invention discloses application of 2-fluorofucose in preparation of a medicine for relieving acute kidney injury, and belongs to the technical field of biology. In-vitro cell experiments and animal experiments prove that 2-fluorofucose can inhibit core fucosylation, competitively inhibit the activity of fucosyltransferase, down-regulate the expression of FUT8 and reduce the core fucosylation level in kidney tissues and renal tubular epithelial cells; by inhibiting core fucosylation, effectively reversing EMT phenotypic transformation induced by hypoxia reoxygenation or ischemia reperfusion, up-regulating E-cadherin expression, down-regulating alpha-SMA and Snail expression and reducing cell migration ability, phosphorylation activation of an ERK pathway is remarkably inhibited, and downstream inflammatory factor release and cell injury signal transduction are blocked, so that the ERK pathway can be used for inhibiting ERK pathway phosphorylation activation. The invention provides application of 2-fluorofucose to preparation of a medicine for relieving acute kidney injury. The invention provides a new choice for treating acute kidney injury, has the outstanding advantages of remarkable curative effect, high safety and the like, and has a wide application prospect.

The present invention belongs to the technical field of quality control products containing tumor markers such as carbohydrate antigens, and specifically relates to a liquid quality control product for tumor markers containing multiple carbohydrate antigens. The liquid quality control product uses human serum as a matrix and contains the following components: A non-analyte includes blocking protein, which is a functional protein modified by fucosylation of the blocking agent. The sugar chain structure containing fucose is introduced through enzymatic hydrolysis and glycosylation, so that it can specifically recognize the fucose-containing Si-Lea epitope shared by carbohydrate antigens; B analytes include carbohydrate antigens and other markers, and other markers include tumor markers and non-tumor-related markers. In response to the problems of significant cross-reaction of carbohydrate antigens and insufficient stability of liquid quality control products, the present invention provides a multi-component synergistic system with blocking protein as the core. By specifically binding to the conserved epitopes of carbohydrate antigens and dynamically blocking cross-reactions, high uniformity, stability and convenient detection of liquid quality control products are achieved.

The invention relates to a nutritional composition comprising a probiotic and a mixture of human milk oligosaccharides (HMOs), wherein the probiotic is the Bifidobacterium bifidum (B. bifidum) R0071 strain (CNCM I-3426) or a strain having at least 97% average nucleotide identity with bacteria of said strain, and the mixture of HMOs comprises or consists essentially of 2'- fucosyllactose (2'-FL) and at least one additional HMO selected from an additional fucosylated HMO, a neutral core HMO, and / or a sialylated HMO. The invention also relates to the nutritional composition for use in supporting or improving gut health, immune system development and anti-inflammatory support, cognitive development, and / or emotional and behavioral development, in a subject.

The present invention provides for the use of recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and / or ability to deliver a therapeutic agent.

Provided herein are methods of producing an antibody composition comprising a desired or predetermined or pre-selected level of total afucosylated (TAF) glycoforms. In exemplary embodiments, the method comprises maintaining glycosylation-competent cells in a cell culture medium comprising fucose and / or glucose at a specific concentration as described herein, depending on the level of TAF glycoforms desired. Related compositions comprising glycosylated proteins and TAF glycoforms thereof are also provided herein. Also provided are cell culture media.

This article describes antibodies or antigen-binding fragments that specifically bind to GPRC5D. Additionally, it includes monovalent antibodies or antigen-binding fragments that specifically bind to GPRC5D. The Fc regions of these antibodies contain K248E and T437R mutations (referred to as “RE mutations”) according to the EU numbering system. The described antibodies, when expressed in host cells lacking fucosylation capacity, exhibit enhanced antibody-dependent cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The invention relates to a composition or a kit of parts comprising a probiotic and at least one human milk oligosaccharide (HMO), wherein the probiotic is the Bifidobacterium bifidum (B. bifidum) HA-132 strain (CNCM I-5898) or a strain having at least 97% average nucleotide identity with CNCM I-5898, and the at least one HMO is selected from a fucosylated HMO, a neutral core HMO, and a sialylated HMO, or is any mixture thereof, for use in supporting or improving cognitive development, emotional and behavioural development, immune system development and anti-inflammatory support, gut barrier function, and / or gut motility, in a subject. The invention further relates to a nutritional composition comprising a probiotic and at least one HMO, wherein the probiotic is the B. bifidum HA-132 strain (CNCM I-5898) or a strain having at least 97% average nucleotide identity with CNCM I-5898, and the at least one HMO is a sialyllactose.

The invention belongs to the field of food, and particularly relates to a nutritional composition and application thereof in improving sleep. The invention provides a nutritional composition. The nutritional composition comprises necessary active ingredients shown as (I) and (II) as follows: (I) casein phosphopeptides and (II) neutral non-fucosylated breast milk oligosaccharides, wherein the casein phosphopeptides are casein phosphopeptides, the casein phosphopeptides are casein phosphopeptides, the casein phosphopeptides are casein phosphopeptides, the neutral non-fucosylated breast milk oligosaccharide at least contains lactose-N-neotetraose, and in the nutritional composition, the mass ratio of the casein phosphopeptides to the lactose-N-neotetraose is 1: (0.1-15.0). According to the invention, the combination of the casein phosphopeptides and the lactose-N-neotetraose can effectively improve the sleep problem, even can improve the anxiety state caused by the sleep problem, and the casein phosphopeptides and the lactose-N-neotetraose also have a synergistic interaction effect.

The present invention relates to fucosylated mammalian milk oligosaccharides (MMO) for use in a method for the prevention and / or treatment of shipping fever in animals, more particularly in farm-bred animals or domesticated animals. More particularly, the present invention relates to fucosylated mammalian milk oligosaccharides (MMO) for use in a method for the prevention and / or treatment of shipping hot pneumonia and / or shipping hot diarrhea in animals, more particularly in farm-bred animals or domesticated animals.

The present invention relates to the technical field of functional enzymes, and in particular to an α-L-fucosidase mutant and an application thereof. The amino acid sequence of the mutant has at least 80% homology to the amino acid sequence of fucosidase SEQ ID NO: 1; the mutant has at least one characteristic sequence of the fucosidase, and the amino acid sequence of the fucosidase is modified, substituted, deleted or added with one or more amino acids to obtain the amino acid sequence of the mutant; the mutant has an amino acid sequence encoded by a nucleotide sequence shown in SEQ ID NO: 2 or its complementary sequence, or a sequence that is different from the nucleotide sequence of the nucleotide sequence shown in SEQ ID NO: 2 or its complementary sequence due to the degeneracy of the genetic code. The mutant provided by the present invention is beneficial to reducing the cost and reaction time in the catalytic reaction of fucosylated compound synthesis.

Disclosed are compositions, systems, and kits for adoptive cell therapy, comprising at least one immune checkpoint inhibitor and at least one immune cell type, wherein the at least one immune cell type is ex vivo fucosylated (fucoACT). Also disclosed are methods of making and using these compositions, systems, and kits.

The invention discloses a kit for detecting plasma IgG glycosylation level and a detection method thereof, and relates to the technical field of biological detection.Plasma IgG is specifically captured through protein A, four biotinylation lectins are combined, sialylation, galactosylation, fucosylation and mannosylation levels of IgG can be synchronously and quantitatively detected, a standardized ELISA system is established, and the kit is used for detecting the plasma IgG glycosylation level. Operation is easy and convenient, repeatability is good, and the problem that multi-dimensional simultaneous detection cannot be achieved in the prior art is solved. The kit is low in cost, does not need complex instruments, is suitable for large-scale clinical popularization, and fills the market blank of commercial IgG glycosylation ELISA kits. Clinical samples of colorectal cancer prove that patients and healthy people can be effectively distinguished, in-vitro risk assessment can be realized by combining a column diagram model, the detection efficiency is excellent, and the method can be expanded to be applied to assessment and monitoring of various tumor and inflammation related diseases, and has high clinical value.

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or vision development in a subject wherein: a) the fucosylated HMO is lactose-N-fucopentasaccharide-I (LNFP-I) and the subject is an infant of up to 12 months of age; and / or b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child.

The invention relates to a method for selective crystallization of 2′-FL from an aqueous solution comprising 2′-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.